Literature DB >> 21989121

Serum pepsinogen test for early detection of gastric cancer in a European country.

Rafael Lomba-Viana1, Mário Dinis-Ribeiro, Fernando Fonseca, Anabela Silva Vieira, Maria José Bento Bento, Helena Lomba-Viana.   

Abstract

AIM: To estimate the adherence of Western individuals to serum pepsinogen (PG) test and its accuracy in the detection of gastric cancer followed by upper gastrointestinal endoscopy.
METHODS: Individuals from the northern region of Portugal, aged between 40 and 79 years, were invited to participate in a blood collection for the determination of serum PG values by ELISA method (Biohit kits). Participants were classified into two groups: positive (PG I ≤70 ng/ml and PG I/ PGII ≤3) and negative (all others). All participants with a positive test and a consecutive random sample of participants with a negative test were subjected to endoscopy with biopsy. All the participants (positive or negative) subjected to endoscopy were followed up over 5 years.
RESULTS: From a total of 13 118 participants, 5326 were men (41%) with a median age of 60 years, and 446 (3.4%) had a positive test. Of these, 274 (61%) were subjected to endoscopy. We observed six gastric cancers, five intestinal and one diffuse type, and three early gastric cancers, representing one cancer per approximately 2200 PG tests or one cancer per 74 positive tests. From these 240 participants with a negative test, three patients with gastric cancer were diagnosed during follow-up (an estimated negative predictive value of 99%). In this study, the PG test showed an estimated sensitivity, specificity, positive predictive value, and negative predictive value of 67, 47, 2, and 99%, respectively.
CONCLUSION: Inhabitants of this high-risk region showed good adherence rate to a gastric cancer detection program based on a PG test followed by upper gastrointestinal endoscopy implemented for the first time. Accuracy estimates were similar to those in Japanese reports, indicating that this methodology could also be used effectively in Western countries with high rates of gastric cancer. Further formal cost-effective studies are however needed.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 21989121     DOI: 10.1097/MEG.0b013e32834d0a0a

Source DB:  PubMed          Journal:  Eur J Gastroenterol Hepatol        ISSN: 0954-691X            Impact factor:   2.566


  21 in total

1.  Helicobacter pylori infection and pepsinogen levels have clinical significance in hypertension patients.

Authors:  Changqing Lu; Helei Jia; Aiguo Xu; Jianming Tang; Gang Xu; Wenbin Yue; Junjie Zhang
Journal:  Int J Clin Exp Med       Date:  2014-12-15

2.  Serum pepsinogen and gastrin-17 as potential biomarkers for pre-malignant lesions in the gastric corpus.

Authors:  Tan Han Loong; Ngiu Chai Soon; Nik Ritza Kosai Nik Mahmud; Jeevinesh Naidu; Rafiz Abdul Rani; Nazefah Abdul Hamid; Marjanu Hikmah Elias; Isa Mohamed Rose; Azmi Tamil; Norfilza M Mokhtar; Raja Affendi Raja Ali
Journal:  Biomed Rep       Date:  2017-09-20

Review 3.  Current issues and future perspectives of gastric cancer screening.

Authors:  Chisato Hamashima
Journal:  World J Gastroenterol       Date:  2014-10-14       Impact factor: 5.742

4.  Detection of gastric atrophy by circulating pepsinogens: A comparison of three assays.

Authors:  Marcis Leja; M Constanza Camargo; Inese Polaka; Sergejs Isajevs; Inta Liepniece-Karele; Dainius Janciauskas; Dace Rudzite; Ilze Kikuste; Aigars Vanags; Ilona Kojalo; Valdis Folkmanis; Arnis Kirsners; Ivars Tolmanis; Charles S Rabkin
Journal:  Helicobacter       Date:  2017-05-29       Impact factor: 5.753

5.  British Society of Gastroenterology guidelines on the diagnosis and management of patients at risk of gastric adenocarcinoma.

Authors:  Matthew Banks; David Graham; Marnix Jansen; Takuji Gotoda; Sergio Coda; Massimiliano di Pietro; Noriya Uedo; Pradeep Bhandari; D Mark Pritchard; Ernst J Kuipers; Manuel Rodriguez-Justo; Marco R Novelli; Krish Ragunath; Neil Shepherd; Mario Dinis-Ribeiro
Journal:  Gut       Date:  2019-07-05       Impact factor: 23.059

6.  Gastric adenocarcinoma screening and prevention in the era of new biomarker and endoscopic technologies: a cost-effectiveness analysis.

Authors:  Jennifer M Yeh; Chin Hur; Zachary Ward; Deborah Schrag; Sue J Goldie
Journal:  Gut       Date:  2015-03-16       Impact factor: 23.059

Review 7.  Gastric cancer: prevention, screening and early diagnosis.

Authors:  Victor Pasechnikov; Sergej Chukov; Evgeny Fedorov; Ilze Kikuste; Marcis Leja
Journal:  World J Gastroenterol       Date:  2014-10-14       Impact factor: 5.742

8.  Serum Pepsinogen as a Biomarker for Gastric Cancer in the United States: A Nested Case-Control Study Using the PLCO Cancer Screening Trial Data.

Authors:  Haejin In; Srawani Sarkar; Jessica Ward; Patricia Friedmann; Michael Parides; Julie Yang; Meira Epplein
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2022-07-01       Impact factor: 4.090

9.  Serum pepsinogen 1 and anti-Helicobacter pylori IgG antibodies as predictors of gastric cancer risk in Finnish males.

Authors:  M Song; M C Camargo; S J Weinstein; G Murphy; N D Freedman; J Koshiol; R Z Stolzenberg-Solomon; C C Abnet; S Männistö; D Albanes; C S Rabkin
Journal:  Aliment Pharmacol Ther       Date:  2017-12-15       Impact factor: 8.171

10.  Endoscopic screening for gastric cancer: A cost-utility analysis for countries with an intermediate gastric cancer risk.

Authors:  Miguel Areia; Manon Cw Spaander; Ernst J Kuipers; Mário Dinis-Ribeiro
Journal:  United European Gastroenterol J       Date:  2017-07-18       Impact factor: 4.623

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.